Predictors of freezing of gait in newly diagnosed Parkinson’s disease: Clinical, dopamine transporter imaging and CSF markers in the PPMI cohort
Objective: To examine whether clinical, dopamine transporter (DAT) imaging and cerebrospinal fluid (CSF) markers can be used to predict the later development of FOG individually…Decreased amyloid-beta in patients with Idiopathic Parkinson’s Disease and white matter hyperintensities
Objective: The aim of this study is to investigate the clinical and biochemical profile of patients with PD with and without WMH. Background: Parkinson’s disease…Microbiota DNA in the blood of patients with Parkinson’s disease
Objective: The aim of this study was to explore the blood microbiota compositions in Chinese patients with Parkinson’s disease (PD). Background: Emerging evidences suggest that…Motor Symptoms in Patients with Parkinson’s Disease – Correlations with Cerebrospinal Fluid C-Reactive Protein
Objective: In this study, we intended to investigate the association between severity of PD motor symptoms and the cerebrospinal fluid (CSF) levels of CRP using…The Prevalence of Tandem Gait Abnormality in Parkinson’s Disease
Objective: To assess the prevalence of tandem gait abnormality in patients with Parkinson’s disease (PD), comparing Hoehn and Yahr (HY) stages 2 and 3. Background:…Pimavanserin Combined With Anti-Dementia Medications for Parkinson Disease Psychosis
Objective: To evaluate the differential antipsychotic effect of pimavanserin, a selective serotonin (5-HT2A) receptor inverse agonist, for Parkinson’s disease psychosis with and without concomitant anti-dementia…Brain Perfusion pattern linked to depressive state in Parkinson’s: An arterial spin labelling MRI study
Objective: To investigate patterns of cerebral blood flow alteration associated with depressive state in Parkinson’s disease (PD) by using principal component analysis of arterial spin…Naturalistic-based UPDRS-III Minimal Clinically Important Difference (MCID) in early PD
Objective: To find the MCID of the UPDRS-III subscale in early PD subjects, when started on a new dopaminergic drug. Background: The concept of Minimally…Pilot study of a new tool to optimize dopaminergic treatment in Parkinson’s disease: The OPTIPARK Scale Project
Objective: Our objective was to develop and pilot test a scale (OPTIPARK) for assessing a patient´s dopaminergic state, allowing the clinician to consider the adjustment…Clinical study on the correlation between Parkinson’s somatosensory evoked potentials and STN-DBS parameters
Objective: Indications for STN-DBS are assessed based on the clinical symptoms. Our test was a clinical study on the correlation between amplitude and latency of…
- « Previous Page
- 1
- …
- 29
- 30
- 31
- 32
- 33
- …
- 177
- Next Page »